269 related articles for article (PubMed ID: 20525710)
1. Inhaled drugs as risk factors for community-acquired pneumonia.
Almirall J; Bolíbar I; Serra-Prat M; Palomera E; Roig J; Hospital I; Carandell E; Agustí M; Ayuso P; Estela A; Torres A;
Eur Respir J; 2010 Nov; 36(5):1080-7. PubMed ID: 20525710
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease.
Gershon A; Croxford R; Calzavara A; To T; Stanbrook MB; Upshur R; Stukel TA
JAMA Intern Med; 2013 Jul; 173(13):1175-85. PubMed ID: 23689820
[TBL] [Abstract][Full Text] [Related]
3. Relationship between the use of inhaled steroids for chronic respiratory diseases and early outcomes in community-acquired pneumonia.
Almirall J; Bolíbar I; Serra-Prat M; Palomera E; Roig J; Hospital I; Carandell E; Agustí M; Ayuso P; Estela A; Torres A;
PLoS One; 2013; 8(9):e73271. PubMed ID: 24039899
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of community-acquired pneumonia in COPD patients with comorbid cardiovascular disease.
Lin SH; Perng DW; Chen CP; Chai WH; Yeh CS; Kor CT; Cheng SL; Chen JJ; Lin CH
Int J Chron Obstruct Pulmon Dis; 2016; 11():3051-3058. PubMed ID: 27980402
[TBL] [Abstract][Full Text] [Related]
5. Inhaled anticholinergic drugs and risk of acute urinary retention.
Afonso AS; Verhamme KM; Stricker BH; Sturkenboom MC; Brusselle GG
BJU Int; 2011 Apr; 107(8):1265-72. PubMed ID: 20880196
[TBL] [Abstract][Full Text] [Related]
6. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
7. The natural history of community-acquired pneumonia in COPD patients: a population database analysis.
Müllerova H; Chigbo C; Hagan GW; Woodhead MA; Miravitlles M; Davis KJ; Wedzicha JA
Respir Med; 2012 Aug; 106(8):1124-33. PubMed ID: 22621820
[TBL] [Abstract][Full Text] [Related]
8. Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma.
Dormuth CR; Glynn RJ; Neumann P; Maclure M; Brookhart AM; Schneeweiss S
Clin Ther; 2006 Jun; 28(6):964-78; discussion 962-3. PubMed ID: 16860179
[TBL] [Abstract][Full Text] [Related]
9. Chronic obstructive pulmonary disease and mortality from pneumonia: meta-analysis.
Loke YK; Kwok CS; Wong JM; Sankaran P; Myint PK
Int J Clin Pract; 2013 May; 67(5):477-87. PubMed ID: 23574107
[TBL] [Abstract][Full Text] [Related]
10. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis.
Andréjak C; Nielsen R; Thomsen VØ; Duhaut P; Sørensen HT; Thomsen RW
Thorax; 2013 Mar; 68(3):256-62. PubMed ID: 22781123
[TBL] [Abstract][Full Text] [Related]
11. Low incidence of paradoxical bronchoconstriction with bronchodilator drugs administered by Respimat Soft Mist inhaler: results of phase II single-dose crossover studies.
Koehler D; Pavia D; Dewberry H; Hodder R
Respiration; 2004; 71(5):469-76. PubMed ID: 15467324
[TBL] [Abstract][Full Text] [Related]
12. Comorbid pulmonary disease and risk of community-acquired pneumonia in COPD patients.
Lin SH; Ji BC; Shih YM; Chen CH; Chan PC; Chang YJ; Lin YC; Lin CH
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1638-44. PubMed ID: 24200282
[TBL] [Abstract][Full Text] [Related]
13. Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat soft mist inhaler.
Hodder R; Pavia D; Dewberry H; Alexander K; Iacono P; Ponitz H; Beck E
Respir Med; 2005 Sep; 99(9):1087-95. PubMed ID: 15893465
[TBL] [Abstract][Full Text] [Related]
14. Potential side effects in patients treated with inhaled corticosteroids and long-acting beta2-agonists.
Korsgaard J; Ledet M
Respir Med; 2009 Apr; 103(4):566-73. PubMed ID: 19136239
[TBL] [Abstract][Full Text] [Related]
15. [Pneumology. Should we fear inhaled anticholinergic bronchodilators?].
Rochat T; Janssens JP
Rev Med Suisse; 2009 Jan; 5(186):135-7. PubMed ID: 19238933
[TBL] [Abstract][Full Text] [Related]
16. Seasonality, risk factors and burden of community-acquired pneumonia in COPD patients: a population database study using linked health care records.
Williams NP; Coombs NA; Johnson MJ; Josephs LK; Rigge LA; Staples KJ; Thomas M; Wilkinson TM
Int J Chron Obstruct Pulmon Dis; 2017; 12():313-322. PubMed ID: 28176888
[TBL] [Abstract][Full Text] [Related]
17. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
Suh DC; Lau H; La HO; Choi IS; Geba GP
Curr Med Res Opin; 2010 Feb; 26(2):297-306. PubMed ID: 19961283
[TBL] [Abstract][Full Text] [Related]
18. Effects of inhaled corticosteroids in monotherapy or combined with long-acting {beta}2-agonists on mortality among patients with chronic obstructive pulmonary disease.
Cyr MC; Beauchesne MF; Lemière C; Aaron SD; Blais L
Ann Pharmacother; 2010 Apr; 44(4):613-22. PubMed ID: 20233915
[TBL] [Abstract][Full Text] [Related]
19. Aetiology of, and risk factors for, recurrent community-acquired pneumonia.
Garcia-Vidal C; Carratalà J; Fernández-Sabé N; Dorca J; Verdaguer R; Manresa F; Gudiol F
Clin Microbiol Infect; 2009 Nov; 15(11):1033-8. PubMed ID: 19673961
[TBL] [Abstract][Full Text] [Related]
20. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease.
Molinos L; Clemente MG; Miranda B; Alvarez C; del Busto B; Cocina BR; Alvarez F; Gorostidi J; Orejas C;
J Infect; 2009 Jun; 58(6):417-24. PubMed ID: 19329187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
